Anesthetic Effect – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Anesthetic Effect – Pipeline Review, H2 2016’, provides an overview of the Anesthetic Effect pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anesthetic Effect, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anesthetic Effect and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Anesthetic Effect

The report reviews pipeline therapeutics for Anesthetic Effect by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anesthetic Effect therapeutics and enlists all their major and minor projects

The report assesses Anesthetic Effect therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anesthetic Effect

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Biolab Farmaceutica Ltda

Drawbridge Pharmaceuticals Pty Ltd

Expanesthetics Inc

Jiangsu Hengrui Medicine Co., Ltd.

Lipicard Technologies Limited

NanoMedex Pharmaceuticals, Inc.

Paion AG

Phosphagenics Limited

Physica Pharma

Primex Pharmaceuticals Oy

Proteus SA

Sphaera Pharma Pvt. Ltd.

Taiwan Liposome Company, Ltd.

The Medicines Company

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Anesthetic Effect Overview 9

Therapeutics Development 10

Pipeline Products for Anesthetic Effect - Overview 10

Pipeline Products for Anesthetic Effect - Comparative Analysis 11

Anesthetic Effect - Therapeutics under Development by Companies 12

Anesthetic Effect - Therapeutics under Investigation by Universities/Institutes 14

Anesthetic Effect - Pipeline Products Glance 15

Late Stage Products 15

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Anesthetic Effect - Products under Development by Companies 19

Anesthetic Effect - Products under Investigation by Universities/Institutes 20

Anesthetic Effect - Companies Involved in Therapeutics Development 21

Biolab Farmaceutica Ltda 21

Drawbridge Pharmaceuticals Pty Ltd 22

Expanesthetics Inc 23

Jiangsu Hengrui Medicine Co., Ltd. 24

Lipicard Technologies Limited 25

NanoMedex Pharmaceuticals, Inc. 26

Paion AG 27

Phosphagenics Limited 28

Physica Pharma 29

Primex Pharmaceuticals Oy 30

Proteus SA 31

Sphaera Pharma Pvt. Ltd. 32

Taiwan Liposome Company, Ltd. 33

The Medicines Company 34

Anesthetic Effect - Therapeutics Assessment 35

Assessment by Monotherapy Products 35

Assessment by Target 36

Assessment by Mechanism of Action 38

Assessment by Route of Administration 40

Assessment by Molecule Type 42

Drug Profiles 43

ABP-700 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

ADV-6209 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

alphaxalone - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

bupivacaine hydrochloride - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Carboetomidate - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

gabafol - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

HSK-3486 - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

LT-1121 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

LT-1123 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Methoxycarbonyl Carboetomidate - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Methoxycarbonyl Etomidate - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

neosaxitoxin - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

PB-5109 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

PHY-301 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

propofol - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

propofol - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

propofol microemulsion - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

remimazolam - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

remimazolam - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

Small Molecule for General Anesthetic Effect - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Small Molecules for General Anesthetic Effect - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Small Molecules to Inhibit NMDA Receptor for Anesthesia - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

SPR-819 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Anesthetic Effect - Dormant Projects 75

Anesthetic Effect - Discontinued Products 77

Anesthetic Effect - Product Development Milestones 78

Featured News & Press Releases 78

Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China 78

Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy 78

Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA 79

Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment 80

Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy 80

Oct 26, 2015: Results of First-in-Man Study with Investigational Anesthetic ABP-700 Presented at ANESTHESIOLOGY 2015 and International Society of Anesthetic Pharmacology Annual Meetings 81

Oct 22, 2015: The Medicines Company To Present Data on Potentially Innovative Surgical Anesthetic at American Society of Anesthesiologists 2015 Meeting 82

Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015 83

Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia 83

Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy 84

Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States 85

Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion 85

Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan 86

Oct 10, 2014: Paion Expects Ono’S Remimazolm Decision On Filing In Japan In November 2014 86

Oct 01, 2014: Two Scientific Remimazolam Presentations Are Accepted for ASA and ACG Meeting in October 2014 86

Appendix 89

Methodology 89

Coverage 89

Secondary Research 89

Primary Research 89

Expert Panel Validation 89

Contact Us 89

Disclaimer 90

List of Tables

List of Tables

Number of Products under Development for Anesthetic Effect, H2 2016 10

Number of Products under Development for Anesthetic Effect – Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 14

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Comparative Analysis by Unknown Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Investigation by Universities/Institutes, H2 2016 20

Anesthetic Effect – Pipeline by Biolab Farmaceutica Ltda, H2 2016 21

Anesthetic Effect – Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2016 22

Anesthetic Effect – Pipeline by Expanesthetics Inc, H2 2016 23

Anesthetic Effect – Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 24

Anesthetic Effect – Pipeline by Lipicard Technologies Limited, H2 2016 25

Anesthetic Effect – Pipeline by NanoMedex Pharmaceuticals, Inc., H2 2016 26

Anesthetic Effect – Pipeline by Paion AG, H2 2016 27

Anesthetic Effect – Pipeline by Phosphagenics Limited, H2 2016 28

Anesthetic Effect – Pipeline by Physica Pharma, H2 2016 29

Anesthetic Effect – Pipeline by Primex Pharmaceuticals Oy, H2 2016 30

Anesthetic Effect – Pipeline by Proteus SA, H2 2016 31

Anesthetic Effect – Pipeline by Sphaera Pharma Pvt. Ltd., H2 2016 32

Anesthetic Effect – Pipeline by Taiwan Liposome Company, Ltd., H2 2016 33

Anesthetic Effect – Pipeline by The Medicines Company, H2 2016 34

Assessment by Monotherapy Products, H2 2016 35

Number of Products by Stage and Target, H2 2016 37

Number of Products by Stage and Mechanism of Action, H2 2016 39

Number of Products by Stage and Route of Administration, H2 2016 41

Number of Products by Stage and Molecule Type, H2 2016 42

Anesthetic Effect – Dormant Projects, H2 2016 75

Anesthetic Effect – Dormant Projects (Contd..1), H2 2016 76

Anesthetic Effect – Discontinued Products, H2 2016 77

List of Figures

List of Figures

Number of Products under Development for Anesthetic Effect, H2 2016 10

Number of Products under Development for Anesthetic Effect – Comparative Analysis, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 35

Number of Products by Top 10 Targets, H2 2016 36

Number of Products by Stage and Top 10 Targets, H2 2016 36

Number of Products by Top 10 Mechanism of Actions, H2 2016 38

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 38

Number of Products by Routes of Administration, H2 2016 40

Number of Products by Stage and Routes of Administration, H2 2016 40

Number of Products by Stage and Molecule Types, H2 2016 42

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports